Fig. 3: Significant differences in normalized protein expression (NPX) in infants with future type 1 diabetes (T1D).
From: The inflammatory path toward type 1 diabetes begins during pregnancy
a Proteins differentiating future T1D (n = 146) and controls (n = 286), based on log2fold change statistics. Controls are defined as children without a future diagnosis of an autoimmune disease, psychiatric condition, or neurodevelopmental disorder. Annotated proteins are significant after false discovery rate (FDR) correction. b Wilcoxon statistics with a two-sided test for group differences (controls and future T1D) for each of the top ten proteins. For means, see Supplementary Data 4 and for full statistics, see Supplementary Data 5. Boxplots show the median (line) and interquartile range (box, 25th–75th percentile) to demonstrate the data distribution, future T1D (n = 146) and controls (n = 286). Whiskers extend to the most extreme values within 1.5 × interquartile range (IQR) of the lower and upper quartiles; points beyond the whiskers are plotted as outliers. Values are displayed as normalized protein expression (NPX) values. c T1D-associated proteins identified as core proteins in Gene Set Enrichment Analysis (GSEA) pathways, and those specifically related to: d cytokines and e the immune system. ADA adenosine deaminase, ARHGEF12 Rho guanine nucleotide exchange factor 12, CASP2 caspase-2, CD40LG CD40 ligand, CD84 CD84 molecule, DBNL drebrin-like protein, DECR1 2,4-dienoyl-CoA reductase 1, EDAR ectodysplasin A receptor, GOBP Gene Ontology Biological Process, GOCC Gene Ontology Cellular Component, GOMF Gene Ontology Molecular Function, HLA-DRA histocompatibility antigen, DR alpha chain, IDS iduronate 2-sulfatase, IL17C interleukin-17C, ITM2A integral membrane protein 2A, LAMA4 laminin subunit alpha-4, LAP3 leucine aminopeptidase 3, LSP1 lymphocyte-specific protein 1, MEPE matrix extracellular phosphoglycoprotein, NTF3 neurotrophin-3, OMD osteomodulin, PDLIM7 PDZ and LIM domain protein 7, PLAUR plasminogen activator urokinase receptor, PLXNA4 plexin A4, PRDX5 peroxiredoxin-5, PTH1R parathyroid hormone 1 receptor, SKAP2 src kinase-associated phosphoprotein 2, SPINT2 serine protease inhibitor, Kunitz type 2, SPRY2 sprouty RTK signaling antagonist 2, STX8 syntaxin-8, TBC1D5 TBC1 domain family member 5, TIMP3 tissue inhibitor of metalloproteinases 3.
